Genmab — Juli 2018
-
God morgen.
-
-
-
act, her udtager man også t-celler og fremstiller i laboratoriet en hybridform af to t-celle-undertyper - Th1 og Th17 - som kombinerer de cancerbekæmpende egnskaber ved Th1-cellerne med evnen hos Th17 til at forny sig selv og regenermere, og som sammen med et cd-38 antistof kan angribe tumorer mere effektivt.
-
Immatics, som Genmab netop har indledt samarbejde med, har en del på bedding inden for ACT i samarbejde med MD Anderson. https://immatics.com/act.html
-
-
Fin artikel om dara sc og amyloidosis (ANDROMEDA studiet) https://www.raredr.com/news/ray-comenzo-md-discusses-andromeda-trial-al-amyloidosis-patients
-
"
The response rates were really stunning even though these patients in the ramp-in didn’t go through the entire course of therapy before the responses were scored. They are still getting treated, obviously, but three-quarters of patients recorded very deep responses" -
"If daratumumab and CyBorD works better than CyBorD alone, we have a new standard of therapy for patients with light chain amyloidosis. In addition, the study is designed to allow patients to have their blood stem cells collected after 6 months of treatment"
.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind